Navigation Links
Schering-Plough Announces Hepatitis C Data Presentations at,Digestive Disease Week (DDW) 2007 Annual Meeting

ing signs or symptoms of these conditions should be withdrawn from therapy. In many but not all cases these disorders resolve after stopping PEGINTRON therapy.

Ribavirin causes hemolytic anemia. Anemia associated with REBETOL therapy may exacerbate cardiac disease that has led to fatal and nonfatal myocardial infarctions. Patients with a history of significant or unstable cardiac disease should not be treated with REBETOL. It is advised that complete blood counts (CBC) be obtained at baseline and at weeks 2 and 4 of therapy or more frequently if clinically indicated.

REBETOL and combination REBETOL/PEGINTRON therapy must not be used by women, or male partners of women, who are or may become pregnant during therapy and during the 6 months after stopping therapy. REBETOL and combination REBETOL/PEGINTRON therapy should not be initiated until a report of a negative pregnancy test has been obtained immediately prior to initiation of therapy. Women of childbearing potential and men must use effective contraception (at least two reliable forms) during treatment and during the 6- month post-treatment follow-up period. Significant teratogenic and/or embryocidal effects have been demonstrated for ribavirin in all animal species in which adequate studies have been conducted. These effects occurred at doses as low as one twentieth of the recommended human dose of REBETOL. If pregnancy occurs in a patient or partner of a patient during treatment or during the 6 months after treatment stops, physicians are encouraged to report such cases by calling (800) 727-7064.

PEGINTRON

There are no new adverse events specific to PEGINTRON as compared to INTRON(R) A (Interferon alfa-2b, recombinant) for Injection; however, the incidence of some (e.g., injection site reactions, fever, rigors, nausea) were higher. The most common adverse events associated with PEGINTRON were "flu- like" symptoms, occurring in approximately 50 percent of patients, which may decrease
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
2. Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:11/26/2014)... -- CARsgen, a leader in the development of Chimeric Antigen ... of cancers, today announced the completion of a series ... -based healthcare private equity fund.   ... of new therapeutics for liver, lung, stomach and brain ... Renji Hospital, the company plans to initiate clinical studies ...
(Date:11/26/2014)... According to the new ... (Electric, Battery, Pneumatic), by Product (Drill, Saw, Stapler, ... Application (Orthopedic, ENT, Oral, Thoracic, Neurology) - Global ... Surgical Instruments Market is estimated to be worth ... is expected to grow at a moderate CAGR ...
(Date:11/26/2014)... YORK , Nov. 25, 2014  Medtronic,s ... Covidien has been widely discussed in the ... it,s also creating a stronger leading player in ... to Kalorama Information.  The healthcare market research firm ... systems will feature a diverse set of solutions ...
Breaking Medicine Technology:CARsgen Completes Series A Financing 2Powered Surgical Instruments Market Worth $2.1 Billion by 2019 2Powered Surgical Instruments Market Worth $2.1 Billion by 2019 3Powered Surgical Instruments Market Worth $2.1 Billion by 2019 4Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 2Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 3
(Date:11/26/2014)... Peoria, Il (PRWEB) November 27, 2014 ... is excited to announce the kick-off of its ... AlignLife encourages people to go to donate to ... will partner with local organizations to distribute the ... December 20th, participating AlignLife locations will be accepting ...
(Date:11/26/2014)... 2014 Recently, DressVe , the ... dresses, has unveiled its 2014 Cyber Monday Sales. Also, ... dresses, up to 90 percent off. The special offer ... Free delivery is provided for orders above $69. , ... shoes, handbags and other fashion accessories. The mission of ...
(Date:11/26/2014)... Boxing Day is traditionally the day following Christmas ... as a "Christmas box", from their bosses or employers. ... of Boxing Day, some people may worry about the ... opportunity, and it has recently announced its “ Tbdress ... its global customers. Then people can buy cheap pants, ...
(Date:11/26/2014)... Norwalk Hospital is pleased to announce ... the American Nurses Credentialing Center (ANCC). , The ... work environments where nurses can flourish. The designation ... Hospital and identifies it as one of the ... organizations’ commitment to nurses and their contributions toward ...
(Date:11/26/2014)... HealthDay Reporter WEDNESDAY, Nov. 26, ... more likely to achieve remission if they maintain a healthy ... that those who were heaviest had almost 65 percent reduced ... of remission. "Medication for rheumatoid arthritis is not as ... study,s lead author and a rheumatologist at the Hospital for ...
Breaking Medicine News(10 mins):Health News:DressVe.com: Best 2014 Special Monday Sales Online 2Health News:Tbdress.com: Best Boxing Day Sales For Ladies Worldwide 2Health News:Norwalk Hospital Announces American Nurses Credentialing Center PATHWAY TO EXCELLENCE® DESIGNATION 2Health News:Norwalk Hospital Announces American Nurses Credentialing Center PATHWAY TO EXCELLENCE® DESIGNATION 3Health News:Weight Could Influence Rheumatoid Arthritis Relief 2Health News:Weight Could Influence Rheumatoid Arthritis Relief 3
... (HealthDay News) -- Cancer patients are often faced with ... effects and even mean the difference between life and ... doctors use plain language in explaining the options, ... medicine at the University of Michigan Medical School and ...
... -- The American College of Physicians (ACP) and the ... commend the Centers for Medicare and Medicaid Services on ... "The American College of Physicians believes that the ... the kind of personalized and coordinated care that patients ...
... Wearable sensors that allow the blind to "see" with ... horizon, thanks to a $2 million award from the ... College of New York and Georgia Institute of Technology ... Frontiers in Research and Innovation" program, will fund a ...
... at the University of California, San Francisco (UCSF) Medical Center ... occurs as healthy brain cells begin to form tumors. ... a common type of brain tumor, at its earliest stage, ... will have to prove safe and effective in clinical trials, ...
... prevention trial evaluating two antiretroviral (ARV)-based approaches for preventing the ... one of two different ARV tablets or of a vaginal ... from the study. The decision to discontinue use of tenofovir ... data concluded that the trial will not be able to ...
... of the American Physical Society,s (APS) Division of Fluid ... from across the physical sciences, engineering, and medicine. Topics ... the quirks of flying; why coffee spills; and how ... The meeting will take place November 20-22, ...
Cached Medicine News:Health News:Cancer Patients Should Ask Doctors to Use Simple Terms 2Health News:Consumers and physicians together applaud Comprehensive Primary Care Initiative 2Health News:City College of New York-led research could lead to wearable sensors for the blind 2Health News:City College of New York-led research could lead to wearable sensors for the blind 3Health News:How normal cells become brain cancers 2Health News:Major HIV prevention trial in women to drop oral tenofovir arm 2Health News:Major HIV prevention trial in women to drop oral tenofovir arm 3Health News:Major HIV prevention trial in women to drop oral tenofovir arm 4Health News:Major HIV prevention trial in women to drop oral tenofovir arm 5Health News:APS Division of Fluid Dynamics meeting: Highlights and media registration 2Health News:APS Division of Fluid Dynamics meeting: Highlights and media registration 3Health News:APS Division of Fluid Dynamics meeting: Highlights and media registration 4Health News:APS Division of Fluid Dynamics meeting: Highlights and media registration 5
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: